GlassScriptPhysician profile
Corey Scott Frucht
NPI 1457606238
$6,601.35
in general payments reported to CMS, 2019-2025
29 companies · $518 in 2025
The $518 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $959 · 2021: $620 · 2022: $856 · 2023: $1,270 · 2024: $984 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,772.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,197.17 | 2019-2025 | |
| Janssen Biotech, INC. | $948.83 | 2019-2025 | Tremfya |
| Genzyme Corporation | $815.35 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $698.08 | 2019-2025 | |
| Amgen INC. | $510.50 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $339.62 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $316.42 | 2019-2025 | Ilumya |
| Lilly USA, LLC | $188.14 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Dusa Pharmaceuticals, INC. | $171.21 | 2019 | |
| Galderma Laboratories, L.P. | $158.23 | 2019-2024 | |
| Ucb, INC. | $146.77 | 2021-2024 | Bimzelx |
| Prugen, INC. Pharmaceuticals | $139.43 | 2019 | |
| Pfizer INC. | $133.69 | 2019-2024 | |
| Merz North America, INC. | $128.71 | 2019-2021 | |
| Leo Pharma INC. | $117.01 | 2019-2025 | Adbry, Anzupgo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $97.70 | 2022 | |
| Allergan, INC. | $94.43 | 2019-2022 | |
| Celgene Corporation | $62.02 | 2019 | |
| Dermavant Sciences, INC. | $50.27 | 2024 | Vtama |
| Epi Health, LLC | $49.11 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.29 | 2023-2024 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $42.90 | 2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $35.17 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.98 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $24.30 | 2019 | |
| Krystal Biotech INC | $23.15 | 2024 | Vyjuvek |
| Almirall LLC | $17.89 | 2021 | |
| Genentech USA, INC. | $16.70 | 2023 | Erivedge |
| Organon LLC | $7.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Frucht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.